logo

Hepatitis C

3rd EU HCV Elimination Policy Summit

Wednesday 24th March 2021 14:00 to 18:15 CET

Securing Wider EU Commitment to the Elimination of HCV

  Online event

Speakers

Chairs

Speakers Image 1
Mr. Bertrand Audoin
International Association of Providers of AIDS Care (IAPAC)
Speakers Image 1
Mr. Bertrand Audoin
International Association of Providers of AIDS Care (IAPAC)
_chair

Bertrand Audoin has been  Vice-President of the International Association of Providers of AIDS Care (IAPAC) since 2014.

He also teaches Ethics and Compliance in Public Health at EDHEC Business School since 2008.

Bertrand is a 1992 EDHEC- and a 2008 French Defense Institute alumni and has been working in the fight against HIV/ AIDS for almost 30 years, starting in New Zealand in 1992. He was Chief Executive Officer of French NGO and fundraiser Sidaction from 1996 to 2011, and Executive Director of the International AIDS Society, from 2011 to 2014.

Speakers Image 2
Prof. Massimo Colombo MD
Liver Centre, San Raffaele Hospital, Milan, Italy
Speakers Image 2
Prof. Massimo Colombo MD
Liver Centre, San Raffaele Hospital, Milan, Italy
_chair

Massimo Colombo is currently Director of the Liver Center at San Raffaele Hospital, Milan, Italy. For the last 3 years he was Director of the Center of Translational Research in Hepatology at Humanitas Hospital, Milan, Ital . Before that he was Chairman of the Division of Gastroenterology and Hepatology and Chairman of the Department of Medicine and Liver, Kidney, Lung, Bone Marrow and Organ Transplantation at IRCCS Maggiore Hospital in Milan, Italy for fifteen years. He has also been a Professor of Medicine and Gastroenterology at the University of Milan for more than 25 years. Professor Colombo gained his medical degree from the University of Milan, before completing a residency in gastroenterology at IRCCS Maggiore Hospital. Subsequently, he undertook an international fellowship in liver diseases at Mount Sinai Hospital in New York, USA (1974-1975), before returning to IRCCS Maggiore Hospital.

Professor Colombo’s research interests include the diagnosis and treatment of viral hepatitis and liver cancer. A member of many professional societies including EASL, AASLD and several Italian societies, he is the recipient of numerous awards including the 2010 European Association Study Liver (EASL) Recognition Award for outstanding medical and scientific contributions, the Italian Association for the Study of the Liver (AISF) Distinguished Service Award, the Thannhauser Medal Award of the German Society of Gastroenterology and the Nelson Fausto Award of the International Liver Cancer Association(ILCA). Professor Colombo was Editor-in-Chief of the Journal of Hepatology from 2005–2009 and currently sits on  the editorial boards of many hepatology journals, is Special Section Editor of Journal of Hepatology (2015-2019), Strategic Advisor of Editor of Liver International (2015-2019) and contributor of Selected Summary for Gastroenterology(2000-2021).He was Associate Editor of Journal of Hepatology  in 1996-2000 and chaired the writing committees of EASL Clinical Practice Guidelines of Benign Liver Tumors in 2014 and of Occupational Liver Diseases in 2017. In September 2016 he was appointed Chairman of EASL International Liver Foundation (Geneva, Switzerland). He has authored more than 500 original manuscripts in peer-reviewed journals, with an H-index of 94(Google Scholar) and more than 27,000 citations.

Speakers Image 3
Prof. Angelos Hatzakis
University of Athens Medical School
Speakers Image 3
Prof. Angelos Hatzakis
University of Athens Medical School
_chair

Angelos Hatzakis, MD, PhD, MSc, served as Professor of Epidemiology & Preventive Medicine and Director of the Department of Hygiene, Epidemiology & Medical Statistics at Athens University Medical School. He was also Head and Founder of the National Retrovirus Reference Center. He trained in Internal Medicine (“Hippokratio” General Hospital of Athens) and Epidemiology (Harvard School of Public Health). He has served in many Executive Committees including the presidency of the Hellenic CDC. Professor Hatzakis is  Co-Chair and the  founder of the Hepatitis B and C Public Policy Association. His research interests cover epidemiology, virology, prevention and public health of viral diseases and oncogenic viruses. He is the author or co-author of more than 300 scientific papers published in journals like Lancet, JAMA, Plos Medicine, British Medical Journal, Annals of Internal Medicine, Proceedings of the National Academy of Science/PNAS, AIDS, Journal of AIDS, Journal of Infectious Diseases, Hepatology, Gastroenterology, Antiviral Therapy, Blood, Cancer Research, Pediatrics etc.

Speakers Image 4
Prof. Harry Janssen
University of Toronto
Speakers Image 4
Prof. Harry Janssen
University of Toronto
_chair

Harry Janssen is Professor of Medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in Hepatology. He currently works at Toronto General Hospital as Chief of Hepatology and Director of the Toronto Centre for Liver Disease. 

Professor Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001 he became a faculty member and in 2006 he was appointed as full Professor of Medicine and Chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013 he came to Toronto where he merged all 3 liver programs into the Toronto Centre for Liver Disease, to become one of the largest liver programs in North America based at the Toronto General Hospital.

Professor Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of Hepatology or Virology.

Speakers Image 5
Prof. Mojca Maticic MD, PhD
Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana
Speakers Image 5
Prof. Mojca Maticic MD, PhD
Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana
_chair

Mojca Maticic is Head of the Viral Hepatitis Unit and Head of the STI Outpatient Service at the Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre in Ljubljana, Slovenia. She is also a Full Professor of Infectious Diseases and Epidemiology at the Faculty of Medicine, University of Ljubljana. After gaining her medical degree, Professor Maticic specialised in internal medicine and in infectious diseases at the University of Ljubljana, before completing a masters and PhD in HIV/AIDS and HCV, respectively. Subsequently, she undertook international postdoctoral training at the Middlesex Hospital and Royal Free Hospital in London, UK. Professor Maticic’s research interests focus on viral infections, primarily viral hepatitis, antiviral treatment and STIs.

An active member of numerous professional societies including EASL (European Association for the Study of the Liver), where she is a member of the Policy and Public Health Committee (PPHC), Hepatitis B&C Public Policy Association (HepB&C PPA), ESCMID (European Society of Clinical Microbiology and Infectious Diseases), and INHSU (International Network for management of Hepatitis in Substance Users), she currently leads a hepatitis C study group at C-EHRN (Correlation-European Harm Reduction Network), serves as an advisor to ECDC (European Center for Disease Control) and the VHPB (Viral Hepatitis Prevention Board), and used to advise at the World Health Organization HIV/Viral Hepatitis/STI Committee. Professor Maticic is also a member of the HIV/AIDS Committee of the Slovene Ministry of Health and a co-author of the National Strategy for the Management of HCV Infection in Slovenia. She leads the Slovene National Viral Hepatitis Expert Board and co-authored the national clinical practice guidelines for the treatment of HCV and HBV infections. She has authored or co-authored more than 450 articles in national and international peer-reviewed journals and organised numerous national and international conferences.

Speakers Image 6
Prof. George V. Papatheodoridis
Medical School of National and Kapodistrian University of Athens
Speakers Image 6
Prof. George V. Papatheodoridis
Medical School of National and Kapodistrian University of Athens
_chair

George Papatheodoridis is Professor in Medicine and Gastroenterology at Medical School of National and Kapodistrian University of Athens and Director of the Academic Gastroenterology Department and Liver Transplantation Unit of “Laiko” General Hospital of Athens, Greece. He has been also the President of the Hellenic Transplant Organization since December 2019.

He was trained in Medicine at the Medical School of Athens University and graduated with excellence (9.2/10) in October 1986. He completed his PhD thesis at the Medical School of Athens University in February 1996. He was trained in Gastroenterology at Tzaneion Hospital of Piraeus, Greece and had a 2-year research fellowship in Hepatology at the Royal Free Hospital of London, UK (01/1997-01/1999).

He has served in many international and national associations. In particular, he was a member of the Scientific Committee/Governing Board of European Association for Study of Liver [EASL] and he is a member of EASL and American Association for Study of Liver Diseases (AASLD, fellow) and founding member and treasurer of Hepatitis B & C Public Policy Association. He is president of Hellenic Foundation of Gastroenterology & Nutrition and was president of the Hellenic Association for Study of Liver and general secretary of Hellenic Society of Gastroenterology.

He has served in several international and national committees, such as co-ordinator (2011-2012) and member (2016-2017) of the panel for HBV EASL Clinical Practice Guidelines, current chair of Scientific Committee for Viral Hepatitis of the Hellenic Center for Control and Prevention of Diseases, current chair of committee for Implementation of National Plan for Hepatitis C Elimination, current Chair of the National Committee for Gastroenterology – Central Health Council.

His main research interest has been focused on viral hepatitis. He has (co-)authored >330 papers published in PubMed journals having total IF >2400 and >17000/25000 citations (h-index 62/77) in Scopus/Google Scholar. He was Associate Editor of Liver International and has served as Editorial Board member of several international journals and as reviewer for all gastroenterology/hepatology journals, many major internal medicine journals (New Engl J Med, Lancet, Ann Intern Med, BMJ etc), ILC/EASL-UEGW abstracts, EU 7th Framework Programme for research and Horizon 2020. He has given >165 lectures, chaired >50 lectures/round tables and presented >320 abstracts in international meetings.

Speakers Image 7
Prof. Markus Peck-Radosavljevic
Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
Speakers Image 7
Prof. Markus Peck-Radosavljevic
Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
_chair

Markus Peck-Radosavljevic, MD MBA, is Professor of Medicine and Chairman at the Department of Gastroenterology & Hepatology, Endocrinology, Rheumatology and Nephrology at Klinikum Klagenfurt in Klagenfurt, Austria.

Prof. Peck is a graduate of the Medical University of Graz Medical School, he did his research training at the Medical University of Graz, University of Alberta in Edmonton Canada, Baylor College of Medicine in Houston Texas, and completed his clinical training in Internal Medicine, Gastroenterology/Hepatology, Infectious Diseases, and Intensive Care Medicine at the Medical University of Vienna, Austria.

He began his research in liver disease in the field of thrombocytopenia in portal hypertension and worked on the role of Thrombopoietin (TPO) in advanced stage liver disease for many years. He has also ran a translational lab testing novel approaches to the treatment of portal hypertension and HCC for many years, while working at the Medical University of Vienna. He was  actively involved in the management of post-OLT hepatitis C ran clinical trials in HCV-infection in hemodialysis and post-OLT patients HIV-HCV coinfection, and most HCC-trials in Austria.

Professor Peck served as Vice-secretary of EASL from 2011 to 2013 and as Secretary General of EASL from April 2013 to April 2015. He also served as the Secretary General of the Austrian Association for Internal Medicine from 2006-2014. He has been a member of the UEG Council since 2015 and Chair of the United European Gastroenterology (UEG) Public Affairs Committee (PAC), which he took over in 2018. Starting 2019, he is also serving as the Secretary General of the International Association for the Study of the Liver (IASL), which he will take over as President in 2021.

Over many years until the end of 2015, Professor Peck led the Portal Hypertension, the HIV-HCV-Coinfection, and the Hepatocellular Carcinoma (HCC) Study Groups at the Medical University of Vienna, Austria, where he conducted a number of clinical trials in these indications as well as on new antivirals in HCV-infection in special indications. Since January 2016, he has taken over as Chair of Internal Medicine and Gastroenterology in Klagenfurt, which also includes the Centralized Endoscopy Service Endocrinology, Rheumatology, Nephrology and the Emergency Medicine service. He has set up a new Clinical trials study unit there and is running a broad range of clinical trials in various different indications, including HCC, NASH, and viral hepatitis.

Speakers Image 8
Prof. Nurdan Tözün MD, FRCP
Acibadem UniversitySchool of Medicine, Turkey
Speakers Image 8
Prof. Nurdan Tözün MD, FRCP
Acibadem UniversitySchool of Medicine, Turkey
_chair

Nurdan Tözün earned her medical degree from Istanbul University Faculty of Medicine and completed her postgraduate training in Internal Medicine and Gastroenterology at the same Faculty.

She worked at Marmara University School of Medicine as head of GI department, Dean of medical school, founder and Director of the first Institute of Gastroenterology of Turkey established in 1992.

She has been president of the Turkish Association for the Study of the Liver (TASL) for 6 years and the Turkish Society of Gastroenterology Prof. Tözün actively worked as a member of various international councils, executive committees or subcommittees including UEG (PAC, Head of E&D Task force and UEG Council member), AGA (Ethics committee), APASL (administrative council) and WGO. She served as the Chairperson of the Training Recognition Committee of the European Board of Gastroenterology and Hepatology.

Her main areas of research and interest are: Viral Hepatitis, colorectal cancer and Inflammatory Bowel diseases.

Prof. Tözün is the author of 145 articles in peer reviewed journals, 69 articles in Turkish, 4 book chapters in English. She received several awards for her studies and accomplishments.

She has concentrated her efforts on the prevention and control of viral hepatitis as well as colorectal cancer in the Mediterranean Region. She is the past president of Mediterranean Task Force for Cancer Control (MTCC), an organization which aims to raise public awareness about cancer.

Since 2008 she has been the Head of Gastroenterology and Internal Medicine departments at Acıbadem University School of Medicine where she acted as founding Dean and Vice-Rector for academic affairs until 2012.

 

Speakers

Speakers Image 9
Prof. Maria Buti
Hospital General Universitari Valle Hebron
Speakers Image 9
Prof. Maria Buti
Hospital General Universitari Valle Hebron
_speaker

Maria Buti earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain. She is currently Professor of Medicine and Chief of Internal Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona.

 Professor Butí has worked in viral hepatitis for the last 35 years, particularly in diagnosis and therapy of hepatitis B and C. She has published more than 450 papers in the field of liver disease. Professor Butí is a former President of the Spanish Association for the Study of Liver Diseases and is currently the   EU EASL Public Health and Policy Councillor. She is an active member of EASL and AASLD and various professional societies.

Speakers Image 10
Prof. Sharon Hutchinson
Glasgow Caledonian University and Health Protection Scotland
Speakers Image 10
Prof. Sharon Hutchinson
Glasgow Caledonian University and Health Protection Scotland
_speaker

Sharon Hutchinson is a Professor of Epidemiology and Population Health at Glasgow Caledonian University and holds an honorary appointment at Health Protection Scotland. She has over 20 years experience in conducting epidemiological research to inform on the design and impact of public health interventions. Authoring over 200 publications and PI/co-I on grants worth over £15 million, she leads a broad translational research programme on the prevention, diagnosis, and treatment of hepatitis C (HCV) and other blood-borne viruses. Her research provided the key evidence to guide a public health response to HCV in Scotland, which culminated in Scottish Government investing significantly in their Action Plan. The evidenced-based National Plan was the stimulus for WHO and the World Hepatitis Alliance staging their inaugural World Hepatitis Summit (involving governments and civil society representatives from over 80 countries) in Glasgow during 2015.

Speakers Image 11
Mr. George Kalamitsis
Liver Patients International
Speakers Image 11
Mr. George Kalamitsis
Liver Patients International
_speaker

George Kalamitsis, is a founding member and Chair of the Board of Liver Patients International (LPI), since 2019  and has been  Chair and founding member of the  Hellenic Liver Patients Association "Prometheus", since 2012.

He is also a founding member of Greek Patients Association and recently (2020) he became a Co-Chair of the ACHIEVE Coalition. In 2017, he was appointed President of the Committee Protecting the Rights of Recipients of Health Services, under the Greek Ministry of Health. He is also a member of the Committee Monitoring the Implementation of the National Action Plan for Hepatitis C, under the Greek Ministry of Health (2018). Since 2016, he has been a member of Hepatitis B & C Public Policy Association. Between 2014 and 2016, he was a Board Member of World Hepatitis Alliance.
George Kalamitsis focuses daily on providing support to people living with liver diseases, as well as on advocating for their rights. Furthermore, he is dedicated to raising awareness, promoting prevention, supporting marginalized populations disproportionally affected by liver diseases and implementing community-based programs. He has been working extensively with multiple stakeholders, focusing on patients’ rights as well as building communication channels with organizations and stakeholders, on a National and International level.

Speakers Image 12
Prof. Jeffrey V. Lazarus
Barcelona Institute for Global Health (ISGlobal) and University of Barcelona
Speakers Image 12
Prof. Jeffrey V. Lazarus
Barcelona Institute for Global Health (ISGlobal) and University of Barcelona
_speaker

Professor Jeffrey V Lazarus serves as head of the health systems team at the Barcelona Institute for Global Health (ISGlobal) and as an Associate Professor at the Faculty of Medicine, University of Barcelona, Spain. He is Vice-Chairman of the board of the EASL International Liver Foundation, a member of the EASL Policy and Public Health Committee, and co-chair of the HIV Outcomes Beyond Viral Suppression Coalition. He is the author of more than 200 publications including a co-author of the Lancet GastroHep Commission on Viral Hepatitis (2019), and lead author of The Lancet HIV series “HIV outcomes beyond viral suppression” (2019) and COVID-SCORE (Nature Medicine and PLOS ONE (2020)).

He has presented at more than 100 conferences, as well as in the Danish, Finnish, and European parliaments, and is on the COLDA, HepHIV, and INHSU conference organising committees. Prof Lazarus is an editorial board member of the International Journal of Drug Policy, HIV Medicine, the Journal of Health Communication and the Journal of Hepatology, where he launched the micro-elimination approach in 2017. He is a member of the Danish, Spanish (AEHVE) and European (ACHIEVE) hepatitis elimination coalitions. Previously, he worked for 11 years at WHO Europe and 3 at the Global Fund as well as serving as the founding director of Health Systems Global and the board chair of the foundation AFEW International.

Prof Lazarus leads four viral hepatitis projects piloting new models of care across Europe and in Africa and is a co-investigator of INTE-AFRICA, a European Commission funded cluster RCT in Tanzania and Uganda. He is also currently a commissioner of the EASL-Lancet European Liver Commission, chair of the HIV 4th 90 Consensus Statement, chair of the NAFLD Public Health Consensus Statement and on the public health taskforce of The Lancet COVID-19 Commission.

Speakers Image 13
Dr. Homie Razavi
Center for Disease Analysis
Speakers Image 13
Dr. Homie Razavi
Center for Disease Analysis
_speaker

Homie Razavi  is the managing director of the CDA Foundation, a non-profit organization dedicated to hepatitis elimination.  Homie led a team that was first to publish the feasibility of hepatitis elimination, brought down the global HCV prevalence from 185 to 71 million, ran the analyses for UNITAID before their decision to fund hepatitis HIV co-infection studies, ran the analyses for the Medicine Patent Pool before their decision to expand to hepatitis, ran the analyses for Gavi before their board’s decision to support HBV birth dose vaccination, and started the Polaris Observatory.  He is currently working on making hepatitis elimination feasible through innovative financing mechanisms.

Homie has a broad background, which includes basic research, business development, commercial development, portfolio management, and decision analysis. He is a fellow in the Society of Decision Professionals and a member of AASLD and EASL.  He is also a member of the World Hepatitis Alliance (WHA) and the CDA Foundation board of directors.  He has co-authored over 70 peered reviewed publications on hepatitis and is a frequent speaker on the subject.

Speakers Image 14
Mr. John F. Ryan
Director Public Health and Food Safety, Country Knowledge, Crisis Management, European Commission
Speakers Image 14
Mr. John F. Ryan
Director Public Health and Food Safety, Country Knowledge, Crisis Management, European Commission
_speaker

John F. Ryan is Director of the Commission Public Health directorate since September 2016.

Previously, in the same department, he was the Head of Unit responsible for a number of public health policy areas (cancer, drugs, promotion, monitoring, infectious diseases).

He was a Commission representative on the Board of the EU Lisbon Drugs Agency, and is currently the Commission representative on the Board of the European Centre for Disease Prevention and Control.

He also had the charge of dealing with tobacco control issues.
Current priorities include the development of an EU cancer plan, antimicrobial resistance, vaccination policies, and the negotiation of financial instruments to support health, including research.

He has previously worked on the completion of the internal market, and on international trade negotiations. He is also an official of the Irish civil service (on leave). He is a fellow of the UK faculty of public health.

Speakers Image 15
Prof. Heiner Wedemeyer
Hannover Medical School
Speakers Image 15
Prof. Heiner Wedemeyer
Hannover Medical School
_speaker

Heiner Wedemeyer has been Professor and Chairman of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School since April 1, 2020. He was Professor and Chairman of the Department of Gastroenterology and Hepatology at the University Clinic Essen between February 2019 and April 2020.

He received his medical degree from the University of Göttingen in 1996 and subsequently started his training in Internal Medicine at Hannover Medical School in Germany. From 1998 to 2000, he was a research fellow in immunology at the Liver Diseases Branch, National Institutes of Health, Bethesda, USA. Since 2001, he completed his training in Internal Medicine and Gastroenterology at Hannover Medical School, where he became Professor of Medicine in 2011.

Professor Wedemeyer has been involved in the scientific coordination of the German Network of Competence on Viral Hepatitis (Hep-Net) and the German Liver Foundation for more than 15 years. Currently, he serves as the Managing Director of the German Hepatitis C-Registry. Heiner Wedemeyer is a member of several scientific organizations and was Secretary General of the European Association for the Study of the Liver (EASL), from 2009 to 2011.

Professor Wedemeyer has a long-term research interest in liver diseases with a main focus on viral hepatitis, liver transplantation and hepatocellular carcinoma. He has been principal investigator in numerous clinical trials, focusing on antiviral therapy and immunotherapy of viral hepatitis B, C, D and E. He has authored over 360 original articles; his current Hirsch-Index is 90 (google scholar; January 2020) and his work has been quoted more than 37.000 times.

Heiner Wedemeyer has received numerous awards including the Hans Popper Award of the International Association of the Study of the Liver in 2002, the Innovation Award of the German Medical Faculties (2011) and the Rudolph-Schoen-Awards (2011). His research has been funded by the Deutsche Forschungsgemeinschaft, the German Ministry of Research and Education, the European Union, the European Association for the Study of the Liver and the Bill and Melinda Gates Foundation.

Official Partners


Financial support

This event has been supported by grants from AbbVie and Gilead Sciences Europe